Reagent composition and kit
By designing reagent compositions with specific contact angles and viscosities, and combining nonionic surfactants and enzyme activity, the problems of insufficient reaction specificity and accuracy after dilution in sdLDL-C determination were solved, achieving high correlation and accurate quantitative results.
Patent Information
- Application Number
- CN202380033164.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-11
- Filing Date
- 2023-04-10
- Publication Date
- 2024-11-19
AI Technical Summary
Existing technologies for determining small dense LDL cholesterol (sdLDL-C) have limitations in terms of reaction specificity and accuracy after sample dilution.
A quantitative method for sdLDL-C is designed by using reagent compositions with specific ranges of contact angles and viscosities, containing nonionic surfactants, cholesterol esterases, cholesterol oxidases, and sphingomyelinase activities, and combining specific enzyme activities and surfactants. The reagent compositions include two steps to improve reaction specificity and accuracy after sample dilution.
The quantitative method for sdLDL-C has achieved excellent reaction specificity and accuracy after sample dilution, and can maintain high correlation with the benchmark method, ensuring the accuracy and reliability of the measurement results.
Smart Images

Figure BDA0005075542800000271 
Figure BDA0005075542800000272 
Figure BDA0005075542800000301
Abstract
Description
Technical Field
[0001] The present invention relates to a reagent composition and a kit. Background Art
[0002] As a technique related to the method for measuring LDL cholesterol, there is a technique described in Patent Document 1 (Japanese Patent Application Laid-Open No. 2000-325097). This document describes a method for measuring lipoprotein cholesterol, which includes the following steps: a first step of selectively causing an enzyme reaction of HDL cholesterol by adding an enzyme and a first surfactant to a sample containing lipoprotein; then, a second step of selectively causing an enzyme reaction of LDL cholesterol by adding a second surfactant; and, measuring a compound consumed or generated by the reaction with the enzyme in the first or second step, thereby measuring HDL cholesterol and / or LDL cholesterol. According to this method, it is possible to provide a method and a reagent for measuring, which do not require a lipoprotein aggregating agent that increases the turbidity of the reaction solution, and the enzyme used is not limited. In the step of reacting LDL cholesterol, LDL cholesterol can be quantified simply and inexpensively without newly adding another enzyme. In addition, HDL cholesterol can be accurately and inexpensively measured without forming lipoprotein aggregation (which would hinder optical measurement) as required, and it is considered to be particularly useful in the field of clinical examinations for arteriosclerosis and the like.
[0003] Prior art literature
[0004] Patent Literature
[0005] Patent Document 1: Japanese Patent Application Publication No. 2000-325097 Summary of the invention
[0006] Problems to be solved by the invention
[0007] The inventors of the present application conducted research on the measurement of small dense Low-Density Lipoprotein (sdLDL-C) in LDL cholesterol and found that the technology described in Patent Document 1 has room for improvement in terms of reaction specificity (specifically, correlation with the benchmark method) and accuracy after sample dilution.
[0008] The present invention provides a technique for measuring sdLDL-C with excellent accuracy and specificity after sample dilution.
[0009] Means for solving problems
[0010] The inventors of the present application conducted research to improve the reaction specificity (specifically, the correlation with the benchmark method) of sdLDL-C quantification and the accuracy after sample dilution. As a result, it was found for the first time that by setting the contact angle of the reagent composition used in the quantification of sdLDL-C to a specific range, the correlation with the ultracentrifugation method as the benchmark was good, and the quantification of sdLDL-C with excellent accuracy after sample dilution could be achieved, thereby completing the present invention.
[0011] According to the present invention, the following reagent composition and kit are provided.
[0012] [1] A reagent composition for use as a first reagent composition in a method for quantifying small, dense LDL cholesterol (sdLDL-C) in a sample, the method comprising:
[0013] a step of allowing the first reagent composition to act on the sample; and
[0014] After the step of allowing the first reagent composition to act on the sample, a step of allowing the second reagent composition for quantifying sdLDL-C to act on the sample to quantify the cholesterol in the remaining lipoprotein,
[0015] The reagent composition comprises a nonionic surfactant,
[0016] The reagent composition has cholesterol esterase activity, cholesterol oxidase activity and sphingomyelinase activity,
[0017] The contact angle between the reagent composition and a polyethylene terephthalate (PET) substrate measured by the following method 1 is 63.0° or more and 67.0° or less.
[0018] (Method 1)
[0019] (1) PET substrate: PET (amorphous polyester) resin sheet, transparent, thickness 2 mm
[0020] (2) Pretreatment: The surface of an unused PET substrate was wiped with a 70% ethanol aqueous solution and the measurement was performed within 5 minutes after wiping.
[0021] (3) Measurement method and conditions: drop method, θ / 2 method, temperature: 15-25°C, syringe: Teflon (registered trademark, the same below) coating 18G, dropping method, dropping amount: 2 μL, measurement is performed 1 second after dropping.
[0022] (4) Calculation of contact angle: Measure 5 times and calculate the average value of the 5 times.
[0023] [2] The reagent composition according to [1], wherein the viscosity of the reagent composition at 5°C measured by the following method 2-1 is 2.5 mPa·s or less.
[0024] (Method 2-1)
[0025] (1) Device: EMS viscometer (Electro Magnetically Spinning Visco meter)
[0026] (2) Measurement method and conditions: Measurement method: electromagnetic rotation method, motor speed: 1000 rpm, holding time: 600 seconds, measurement temperature: 5°C, sequence loop: 1 time, sample: 500 μL
[0027] (3) Calculation of viscosity: The measurement was performed 5 times, and the average value of the 5 times was calculated.
[0028] [3] The reagent composition according to [1] or [2], wherein the viscosity of the reagent composition at 37°C measured by the following method 2-2 is 1.05 mPa·s or less.
[0029] (Method 2-2)
[0030] (1) Device: EMS viscometer (Electro Magnetically Spinning Visco meter)
[0031] (2) Measurement method and conditions: Measurement method: electromagnetic rotation method, motor speed: 1000 rpm, holding time: 600 seconds, measurement temperature: 37°C, sequential cycle: 1 time, sample: 500 μL
[0032] (3) Calculation of viscosity: The measurement was performed 5 times, and the average value of the 5 times was calculated.
[0033] [4] The reagent composition according to any one of [1] to [3], wherein the nonionic surfactant comprises polyoxyethylene monostyrenated phenyl ether.
[0034] [5] The reagent composition according to [4], wherein the degree of polymerization n of the polyoxyethylene in the polyoxyethylene monostyrenated phenyl ether is 5 to 80.
[0035] [6] The reagent composition as described in [4] or [5], wherein the content of the polyoxyethylene monostyrenated phenyl ether in the reagent composition is 0.05% (w / v) to 0.6% (w / v) relative to the reagent composition as a whole.
[0036] [7] The reagent composition according to any one of [1] to [6], wherein the reagent composition comprises any one of a hydrogen donor and a coupling agent.
[0037] [8] The reagent composition according to any one of [1] to [7], wherein the reagent composition further has ascorbic acid oxidase activity.
[0038] [9] The reagent composition according to any one of [1] to [8], further comprising at least one activity selected from the group consisting of peroxidase activity and catalase activity.
[0039]
[10] A kit for quantifying the sdLDL-C in the sample, the kit comprising:
[0040] A first reagent composition comprising the reagent composition described in any one of [1] to [9]; and
[0041] A second reagent composition for quantifying the aforementioned sdLDL-C.
[0042]
[11] The kit according to
[10] , wherein the second reagent composition has peroxidase activity.
[0043] Effects of the Invention
[0044] According to the present invention, it is possible to provide a technique for measuring sdLDL-C that is excellent in reaction specificity (specifically, correlation with a standard method) and accuracy after sample dilution. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] [ Figure 1 ] is a graph showing the evaluation results of the accuracy of the measured value of sdLDL-C after sample dilution.
[0046] [ Figure 2 ] is a graph showing the evaluation results of the reaction specificity (correlation with the benchmark method) of the measured value of sdLDL-C.
[0047] [ Figure 3 ] is a graph showing the correlation between the reaction specificity (correlation coefficient in correlation with the standard method) of the measured value of sdLDL-C and the contact angle.
[0048] [ Figure 4 ] is a graph showing the evaluation results of the dilution linearity of the measured value of sdLDL-C.
[0049] [ Figure 5 ] is a graph showing the evaluation results of the dilution linearity of the measured value of sdLDL-C. DETAILED DESCRIPTION
[0050] The following describes the embodiments. In the present embodiment, the composition such as the assay reagent may contain each component alone or may contain two or more components in combination. In addition, in the present specification, the numerical range "x to y" means "above x and below y", and both the lower limit x and the upper limit y are included.
[0051] First, lipoprotein will be described.
[0052] Lipoproteins are roughly divided into very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). LDL is further divided into small, dense LDL lipoprotein (sdLDL) and other subfractions. sdLDL is sometimes called small particle LDL, small LDL (SLDL), dense LDL, small, dense LDL, and other LDL is sometimes called large LDL (L LDL) and light LDL.
[0053] These lipoprotein fractions and subfractions can be distinguished by particle size or specific gravity.
[0054] The diameter of the lipoprotein particle size varies depending on the report, for example, VLDL is 30 nm to 80 nm (or 30 nm to 75 nm), LDL is 22 nm to 28 nm (or 19 nm to 30 nm), and HDL is 7 to 10 nm.
[0055] Regarding the specific gravity of lipoprotein, for example, VLDL is 1.006 or less, LDL is 1.019 to 1.063, and HDL is 1.063 to 1.21.
[0056] Among lipoproteins, the LDL particle diameter can be measured by, for example, gradient gel electrophoresis (GGE) (JAMA, 260, p. 1917-21, 1988), NMR (HANDBOOK OF LIPOPROTEIN TESTING 2nd Edition, edited by Nader Rifai et al., p. 609-623, AACC PRESS: The Fats of Life Summer 2002, LVDD 15YEAR ANNIVERSARY ISSUE, Volume AVI No. 3, p. 15-16). In addition, the specific gravity can be determined based on, for example, analysis using ultracentrifugation (Atherosclerosis, 106, p. 241-253, 1994: Atherosclerosis, 83, p. 59, 1990).
[0057] In the present embodiment, the sdLDL to be measured generally refers to a subfraction having a diameter of about 22.0 to about 25.5 nm in the LDL fraction, or a subfraction having a specific gravity of 1.040 to 1.063.
[0058] The reason why LDL is divided into sub-fractions according to size is that the arteriosclerosis inducibility of LDL with a small particle size is high, and the malignancy is higher in LDL, so it is necessary to measure the smaller one in LDL separately. The distribution of LDL inner diameter and specific gravity is continuous, and it is impossible to clearly distinguish the specific gravity to what extent the malignancy is particularly high. Therefore, the above-mentioned specific gravity of 1.040 to 1.063 is not a value established as a characteristic of sdLDL, but a value of the high specific gravity side after the specific gravity range of 1.019 to 1.063 of LDL, which can be called a determined value, is separated by a central point. For example, for the specific gravity of sdLDL, it is classified as 1.044 to 1.060 (Atherosclerosis: 106 241-2531994) in other reports. The specific gravity of sdLDL is set to what range, which is slightly different due to different reporters, but the presence of sdLDL is related to clinical malignancy when identified in this range.
[0059] In this specification, when referred to as sdLDL, it specifically refers to LDL with a high specific gravity among LDL and a greater clinical atherosclerosis-inducing potential than other LDL. In addition, sdLDL preferably refers to LDL belonging to a specific gravity range higher than the central point in the specific gravity range of LDL, and more preferably refers to LDL belonging to a specific gravity range of 1.044 to 1.063. In addition, when referred to as lipoproteins other than LDL, it refers to VLDL or HDL, and sometimes also includes chylomicrons and IDL (intermediate density lipoprotein).
[0060] The inventors of the present application have conducted research to improve the accuracy of quantifying sdLDL-C in a sample. As a result, it was confirmed that if sdLDL-C is to be quantified by a method including a step of allowing a first reagent composition to act on a sample (first step), and then allowing a second reagent composition for quantifying sdLDL cholesterol (sdLDL-C) to act to quantify the cholesterol in the residual lipoprotein (second step), it is important to highly control the selectivity of the first reagent composition for the action on LDL other than sdLDL in the first step. More specifically, it was found that in the first step, it is important for the first reagent composition to selectively act on LDL other than sdLDL. When the selectivity is too low, that is, when the first reagent composition is a reagent that is also easy to act on sdLDL as the object of measurement, there is a concern that the accuracy of the quantification of sdLDL-C in the sample in the second step will be reduced.
[0061] Therefore, the inventors of the present application conducted further research to make the selectivity of the action of the first reagent composition more ideal, and found that by making the first reagent composition have a specific enzyme activity and making it have a contact angle within a specific range, it is possible to stably obtain a first reagent composition that acts highly selectively on LDL other than sdLDL and can achieve reaction specificity (correlation with the benchmark method) and excellent accuracy after sample dilution for quantification of sdLDL-C.
[0062] In this embodiment, the first reagent composition contains specific components and has a contact angle within a specific range, and therefore can be suitably used for quantification of sdLDL-C, and can achieve excellent accuracy in the measurement of sdLDL-C.
[0063] For example, the first reagent composition is used in combination with the second reagent composition described below to quantify sdLDL-C.
[0064] Hereinafter, each reagent composition will be described in more detail.
[0065] (Reagent composition (first reagent composition))
[0066] In this embodiment, the reagent composition is a reagent composition used as the first reagent composition in the following method for quantifying small dense LDL cholesterol (sdLDL-C) in a sample, the method comprising: a process of allowing the first reagent composition to act on the sample; and, after the process of allowing the first reagent composition to act on the sample, a process of allowing a second reagent composition for quantifying sdLDL-C to act on the sample, thereby quantifying the cholesterol in the residual lipoprotein.
[0067] Hereinafter, the reagent composition used as the first reagent composition is also simply referred to as the "first reagent composition".
[0068] The first reagent composition contains a nonionic surfactant and has cholesterol esterase activity, cholesterol oxidase activity, and sphingomyelinase activity. Furthermore, the contact angle between the first reagent composition and a polyethylene terephthalate (PET) substrate measured by the following method 1 is 63.0° or more and 67.0° or less.
[0069] (Method 1)
[0070] (1) PET substrate: PET (amorphous polyester) resin sheet, transparent, thickness 2 mm
[0071] (2) Pretreatment: The surface of an unused PET substrate was wiped with a 70% ethanol aqueous solution and the measurement was performed within 5 minutes after wiping.
[0072] (3) Measurement method and conditions: drop method, θ / 2 method, temperature: 15-25°C, syringe: Teflon-coated 18G, dropping method, dropping amount: 2 μL, measurement is performed 1 second after dropping.
[0073] (4) Calculation of contact angle: Measure 5 times and calculate the average value of the 5 times.
[0074] In the above (2), the PET substrate was wiped clean of dust etc. before measurement. Since static electricity affects the contact angle, the substrate was wiped to avoid friction etc. as much as possible, and the measurement was performed within 5 minutes.
[0075] In the present embodiment, specifically, the contact angle is a static contact angle measured using, for example, DMo-901, 701, 601, 501, DMC-MC3 or the like manufactured by Kyowa Interface Chemical Co., Ltd.
[0076] The inventors of the present application have discovered for the first time that by making the contact angle between the first reagent composition and the PET substrate in the sdLDL-C measuring reagent be within a specific range, it is possible to achieve quantification of sdLDL LC with excellent reaction specificity (correlation with the benchmark method) and accuracy after sample dilution. The reason is not necessarily clear, but it is considered as follows. In the quantification of sdLDL-C, for example, the first reagent composition removes cholesterol from lipoproteins other than sdLDL in the first step, but at this time, the contact angle may be related to the accuracy after sample dilution. Although the reason is unclear, it is believed that when the sample is diluted, the protein components and the measurement object (sdLDL) contained in the sample will be diluted, so when mixed with the first reagent product, sdLDL is mistakenly reacted due to its influence, and sdLDL-C may be removed. By controlling the contact angle, this erroneous reaction can be suppressed, so sdLDL-C can be estimated more accurately. In addition, it is predicted that when the contact angle deviates from the specific range, even if the sample is not diluted, the reaction between the lipoprotein contained in the sample and the nonionic surfactant and the specific enzyme in the first reagent composition will change when it is mixed with the first reagent composition in the first step. It is believed that due to this erroneous reaction, it is difficult to achieve accurate sdLDL-C measurement, and the correlation with the benchmark method regarding reaction specificity is reduced. Here, the so-called benchmark method is specifically an ultracentrifugation method.
[0077] From the viewpoint of further improving the reaction specificity (correlation with the standard method) of sdLDL-C measurement and the accuracy after sample dilution, the contact angle between the reagent composition and the PET substrate is 63.0° or more, preferably 63.8° or more.
[0078] In order to further improve the reaction specificity (correlation with the standard method) of sdLDL-C measurement, the contact angle between the reagent composition and the PET substrate is 67.0° or less, preferably 66.5° or less, and more preferably 66.0° or less.
[0079] In this embodiment, the contact angle with the PET substrate can be controlled by appropriately selecting the type, combination, and amount of each component included in the first reagent composition, for example. Among these, for example, adjusting the type and amount of surfactant, the type and amount of enzyme or protein can be cited as factors for making the contact angle with the PET substrate within a desired numerical range.
[0080] (Viscosity)
[0081] Specifically, the first reagent composition is in the form of a liquid.
[0082] The viscosity of the first reagent composition at 5°C may be, for example, 2.5 mPa·s or less, preferably 2.2 mPa·s or less, and more preferably 2.0 mPa·s or less, from the viewpoint of improving the accuracy of measurement.
[0083] The viscosity of the first reagent composition at 5° C. may be, for example, 1.6 mPa·s or more, or, for example, 1.8 mPa·s or more.
[0084] From the viewpoint of improving the accuracy of measurement, the viscosity of the first reagent composition at 37° C. is preferably 1.05 mPa·s or less, more preferably 1.00 mPa·s or less, and even more preferably 0.95 mPa·s or less.
[0085] The viscosity of the first reagent composition at 37° C. may be, for example, 0.80 mPa·s or more, or, for example, 0.90 mPa·s or more.
[0086] Here, the viscosity of the first reagent composition at each temperature was measured by the following method 2. In method 2, the method in which the measurement temperature was set to 5° C. was method 2-1, and the method in which the measurement temperature was set to 37° C. was method 2-2.
[0087] (Method 2)
[0088] (1) Device: EMS viscometer (Electro Magnetically Spinning Visco meter)
[0089] (2) Measurement method and conditions: Measurement method: electromagnetic rotation method, motor speed: 1000 rpm, holding time: 600 seconds, measurement temperature: 5°C (method 2-1) and 37°C (method 2-2), sequential cycle: 1 time, sample: 500 μL
[0090] (3) Calculation of viscosity: The measurement was performed 5 times, and the average value of the 5 times was calculated.
[0091] In the present embodiment, the viscosity is measured using, for example, EMS-1000 manufactured by Kyoto Electronics Industries, Ltd.
[0092] The inventors of the present application have also discovered for the first time that by making the viscosity of the first reagent composition in the sdLDL-C measurement reagent within a specific range, it is possible to achieve more accurate quantification of sdLDL-C. The reason is not necessarily clear, but it is believed to be as follows. In the quantification of sdLDL-C, during the measurement, for example, the reagent probe sucks in a certain amount of the first reagent composition and discharges it into the reaction pool. It is believed that when the viscosity of the first reagent composition used in the process of removing cholesterol from lipoproteins other than sdLDL is too high, the discharge amount and the removal amount may change due to the viscosity, but by accurately controlling the viscosity, the liquid separation of the reagent can be appropriately controlled, so that the result can more accurately measure sdLDL-C.
[0093] The first reagent composition is a composition containing a nonionic surfactant and having a specific enzyme activity, so when the first reagent composition is added to a sample, for example, it can act on and remove lipoproteins other than sdLDL in the sample. In addition, cholesterol in lipoproteins other than sdLDL, especially cholesterol in lb LDL, can be stably extracted out of the reaction system.
[0094] Here, "the surfactant acts (reacts)" means that the surfactant degrades the lipoprotein and the cholesterol in the lipoprotein is released. For example, when it is called "a surfactant that acts on lipoproteins other than sdLDL (reacts with lipoproteins other than sdLDL)", it is not required that the surfactant does not act on sdLDL at all, as long as it mainly acts on lipoproteins other than sdLDL. When it is called "a surfactant that acts on LDL other than sdLDL (reacts with LDL other than sdLDL)", it is also the same as long as the surfactant mainly acts on LDL other than sdLDL. "Removal" means that the substance in the test sample is degraded, and its degradation product cannot be detected in the next step. That is, "removing cholesterol from lipoproteins other than sdLDL" means that lipoproteins other than sdLDL in the test sample are degraded, and cholesterol in these lipoproteins as their degradation products cannot be detected in the subsequent steps. Similarly, “removing cholesterol from LDL other than sdLDL” means that cholesterol from LDL other than sdLDL in the test sample cannot be detected in the subsequent step.
[0095] "Exporting to the outside of the reaction system" specifically means: in order to prevent the cholesterol contained in HDL, VLDL, L LDL, etc. from affecting the quantification of sdLDL-C, the cholesterol contained in HDL, VLDL, L LDL, etc. is removed, agglomerated, or inhibited so that it does not react in the subsequent steps.
[0096] Hereinafter, the components contained in the first reagent composition will be described in more detail.
[0097] (Surfactant)
[0098] The first reagent composition contains at least a nonionic surfactant. Specifically, the surfactant is a surfactant that acts on lipoproteins other than sdLDL, and more preferably a surfactant that acts on lipoproteins other than sdLDL and does not act on sdLDL.
[0099] From the viewpoint of further improving the accuracy and specificity of the sample dilution in the determination of sdLDL-C, the nonionic surfactant is preferably a polyoxyethylene derivative, more preferably a polyoxyethylene polycyclic phenyl ether derivative, further preferably one or two selected from the group consisting of polyoxyethylene benzyl phenyl ether derivatives and polyoxyethylene styrenated phenyl ether derivatives, more preferably including polyoxyethylene monostyrenated phenyl ether (POE monostyrenated phenyl ether). From the same viewpoint, it is also preferred that the nonionic surfactant includes a polyoxyethylene benzyl phenyl ether derivative and a polyoxyethylene styrenated phenyl ether derivative.
[0100] POE monostyrenated phenyl ether can be composed of a plurality of compounds having different degrees of polymerization of the POE moiety. In this case, from the viewpoint of improving the accuracy of quantification of sdLDL-C, the average degree of polymerization of ethylene oxide is, for example, 1 or more, preferably 5 or more, more preferably 10 or more, and, for example, 100 or less, preferably 80 or less, more preferably 50 or less, further preferably 40 or less, and, for example, 30 or less.
[0101] Here, the average degree of polymerization can be obtained from the intensity of the oxyethylene signal of POE monostyrenated phenyl ether measured by NMR. For example, in the NMR spectrum of the TMS derivative of POE monostyrenated phenyl ether, the intensity of the protons (9) of the TMS group at 0.08 ppm can be used as a reference, and the average degree of polymerization can be calculated using the ratio of the signal intensity of the methylene protons (4) of the POE part at 3.5 ppm.
[0102] In order to more stably improve the accuracy of quantification of sdLDL-C, it is preferred to contain one or more selected from the group consisting of compounds having an average degree of polymerization n of oxyethylene of POE monostyrenated phenyl ether of n=10 to 20.
[0103] Here, the degree of polymerization of the ethylene oxide of the components constituting POE monostyrenated phenyl ether can be determined by structural analysis based on liquid chromatography-mass spectrometry. For example, if the POE monostyrenated phenyl ether in the first reagent composition is separated by liquid chromatography (LC) and then introduced into a quadrupole time-of-flight mass spectrometer (QTOF mass spectrometer), a mass spectrum formed by peaks separated by 44 amu can be obtained based on the difference in the degree of polymerization of the ethylene oxide of each component. The degree of polymerization of the ethylene oxide of each component can be calculated by subtracting the mass number (MW198) of monostyrenated phenol from the molecular weight calculated from the m / z of each peak and dividing by 44. In addition, the chemical composition (C 198) of monostyrenated phenol can be subtracted from the composition formula obtained from the accurate mass for each peak. 14 H 14 O), or by product ion scanning and detailed structural analysis, thereby analyzing the polymerization degree of ethylene oxide in each component.
[0104] From the viewpoint of improving the accuracy in the quantification of sdLDL-C, the content of POE monostyrenated phenyl ether in the first reagent composition is preferably 0.01% (w / v) or more, more preferably 0.03% (w / v) or more, further preferably 0.05% (w / v) or more, and further more preferably 0.1% (w / v) or more, relative to the first reagent composition as a whole.
[0105] In addition, from the same point of view, the content of POE monostyrenated phenyl ether in the first reagent composition is preferably 0.6% (w / v) or less, more preferably 0.4% (w / v) or less, further preferably 0.35% (w / v) or less, and further more preferably 0.3% (w / v) or less, relative to the first reagent composition as a whole.
[0106] Here, POE monostyrenated phenyl ether is available as an industrial raw material or a research reagent, and for example, a commercially available product can be used.
[0107] In addition, for example, POE monostyrenated phenyl ether can be produced and used. Specifically, it can be produced by the following method and conditions.
[0108] That is, POE monostyrenated phenyl ether can be obtained by adding a predetermined amount of ethylene oxide to monostyrenated phenol in the presence of a basic catalyst. Examples of the basic catalyst include sodium hydroxide, potassium hydroxide, and alkali metal alkoxides. The addition reaction temperature is preferably 120 to 200°C.
[0109] On the other hand, styrenated phenol can be obtained by alkylating phenol and styrene in the presence of an acid catalyst at a temperature of 70°C to 200°C. As the acid catalyst, inorganic acids such as sulfuric acid and phosphoric acid, organic acids such as p-toluenesulfonic acid and methanesulfonic acid, Lewis acids such as boron trifluoride ether complex, etc. can be used. In this reaction, by controlling the equivalent ratio of phenol to styrene, the type of acid catalyst, the reaction temperature and other conditions, a monostyrenated phenol having one styrene bonded to the phenol and benzene rings can be obtained.
[0110] Monostyrenated phenol can be synthesized, for example, by adding styrene dropwise to phenol under a phosphoric acid catalyst to carry out an alkylation reaction, and then adding sulfuric acid or a magnesium sulfate catalyst to remove unreacted phenol and styrene to terminate the alkylation reaction. At this time, the amount of the phosphoric acid catalyst used is preferably 0.001 to 0.01 equivalent relative to phenol. The amount of the sulfuric acid or magnesium sulfate catalyst used is preferably 2% to 10% by mass based on the mass of the phosphoric acid catalyst. In addition, the equivalent ratio of phenol to styrene is preferably 0.9 to 1.3 based on the equivalent ratio of styrene to phenol.
[0111] Next, after the alkylation reaction is completed, an aqueous solution of sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide or the like may be added to neutralize the alkylation reaction product, and the generated neutralization salt may be removed by filtration to recover the monostyrenated phenol.
[0112] Then, in a pressure-resistant container such as an autoclave, potassium hydroxide is used as a catalyst to carry out an addition reaction between the obtained monostyrenated phenol and ethylene oxide under heating and pressure, thereby obtaining POE monostyrenated phenyl ether. The heating and pressurizing conditions are set to, for example, a pressure of 1.5 kg / cm 3 and a temperature of about 130° C. In addition, the number of repeating units of ethylene oxide units, that is, the degree of polymerization of ethylene oxide can be adjusted by adjusting the molar ratio of ethylene oxide to 1 mol of monostyrenated phenol.
[0113] In the above method, as styrenated phenol, a mixture of monostyrenated phenol, distyrenated phenol having two styrenes bonded thereto, and tristyrenated phenol having three styrenes bonded thereto is obtained. Monostyrenated phenol may be separated and purified from the mixture and used.
[0114] The POE monostyrenated phenyl ether in the first reagent composition can be confirmed by, for example, a method of analyzing by combining IR, NMR, LC-MS, etc. As a method of determining the structure of the POE monostyrenated phenyl ether in the first reagent composition, there can be mentioned a method of analyzing by using LC / MS / MS and NMR.
[0115] The concentration of POE monostyrenated phenyl ether in the first reagent composition can be calculated by, for example, HPLC or LC / MS measurement. The concentration of POE monostyrenated phenyl ether in the first reagent composition can also be obtained by NMR measurement.
[0116] From the viewpoint of allowing the nonionic surfactant to stably act on lipoproteins other than sdLDL and further improving the dilution linearity and the accuracy after sample dilution, the concentration of the nonionic surfactant in the first reagent composition is preferably 0.01% (w / v) or more, more preferably 0.025 (w / v) or more, further preferably 0.03% (w / v) or more, further preferably 0.05% (w / v) or more, further preferably 0.075% (w / v) or more, further preferably 0.1% (w / v) or more, further preferably 0.125% (w / v) or more, further preferably 0.25% (w / v) or more, relative to the entire composition of the first reagent composition.
[0117] In addition, the concentration of the nonionic surfactant in the first reagent composition is preferably 1.5% (w / v) or less, more preferably 1.0% (w / v) or less, further preferably 0.875% (w / v) or less, further more preferably 0.75% (w / v) or less, further more preferably 0.6% (w / v) or less, and further preferably 0.3 (w / v) or less, relative to the entire composition of the first reagent composition.
[0118] The nonionic surfactant in the first reagent composition can be identified by, for example, a method of analyzing by combining IR, NMR, LC-MS, etc. As a method of determining the structure of the nonionic surfactant in the first reagent composition, there can be mentioned a method of analyzing by using LC-MSMS or NMR.
[0119] (Enzyme)
[0120] The first reagent composition has cholesterol esterase (CHE) activity, cholesterol oxidase (COO) activity, and sphingomyelinase (SMase) activity, thereby making the first reagent composition act more stably on lipoproteins other than sdLDL and extracting the cholesterol out of the reaction system.
[0121] In addition, specifically, the first reagent composition contains an enzyme having cholesterol esterase activity, an enzyme having cholesterol oxidase activity, and an enzyme having sphingomyelinase activity. More specifically, the first reagent composition contains cholesterol esterase, cholesterol oxidase, and sphingomyelinase.
[0122] As cholesterol esterase, cholesterol oxidase, peroxidase and catalase, for example, enzymes derived from bacteria or fungi, or enzymes derived from plants can be used.
[0123] Here, "having cholesterol esterase activity" specifically means that cholesterol esterase is present and a reaction catalyzed by cholesterol esterase can occur. The same applies to other enzyme activities such as cholesterol oxidase activity.
[0124] From the viewpoint of more stably exporting cholesterol in lipoproteins other than sdLDL to the outside of the reaction system, the cholesterol esterase activity of the first reagent composition is preferably 50 U / L or more, more preferably 100 U / L or more, and is preferably 3000 U / L or less, more preferably 2500 U / L or less, further preferably 2000 U / L or less, further more preferably 1000 U / L or less, and can be, for example, 1800 U / L or less, or, for example, 1500 U / L or less.
[0125] From the same point of view, the cholesterol oxidase activity of the first reagent composition is preferably 100 U / L or more, more preferably 150 U / L or more, and is preferably 800 U / L or less, more preferably 750 U / L or less, further preferably 700 U / L or less, further preferably 650 U / L or less, and further preferably 600 U / L or less.
[0126] The first reagent composition has sphingomyelinase activity and can therefore enhance reactivity to lipoproteins other than sdLDL, particularly L LDL, in the step (first step described below) of releasing cholesterol in lipoproteins other than sdLDL and extracting it out of the reaction system.
[0127] From the viewpoint of more stably exporting cholesterol in lipoproteins other than sdLDL to the outside of the reaction system, the sphingomyelinase activity of the first reagent composition is preferably 100 U / L or more, more preferably 200 U / L or more, and is preferably 3000 U / L or less, more preferably 2800 U / L or less.
[0128] From the viewpoint of more stably exporting cholesterol in lipoproteins other than sdLDL to the outside of the reaction system, the first reagent composition preferably further has at least one activity selected from the group consisting of peroxidase (POD) activity and catalase activity. The first reagent composition more preferably further comprises at least one enzyme selected from the group consisting of an enzyme having peroxidase activity and an enzyme having catalase activity, more preferably further comprises at least one of peroxidase and catalase, and further preferably further comprises catalase.
[0129] From the viewpoint of more stably exporting cholesterol in lipoproteins other than sdLDL to the outside of the reaction system, the peroxidase activity of the first reagent composition is preferably 200 U / L or more, more preferably 300 U / L or more, and preferably 3000 U / L or less, more preferably 2500 U / L or less, and preferably, for example, 2000 U / L or less. In addition, the peroxidase activity of the first reagent composition may be, for example, 5000 U / L or less, or, for example, 4000 U / L or less.
[0130] From the viewpoint of stably removing hydrogen peroxide generated when the first reagent composition is applied to a sample and more stably exporting cholesterol in lipoproteins other than sdLDL in the sample to the outside of the reaction system, the catalase activity of the first reagent composition is preferably 100 KU / L or more, more preferably 200 KU / L or more, and is preferably 2000 KU / L or less, more preferably 1500 KU / L or less.
[0131] The cholesterol oxidase activity, cholesterol esterase activity, sphingomyelinase activity, peroxidase activity, and catalase activity of the first reagent composition can be measured, for example, by the following methods.
[0132] In the determination of cholesterol oxidase activity, a 6mM cholesterol solution (dissolved in isopropanol) is used as a substrate solution. A diluent (0.1M phosphate buffer, TritonX100, pH7.0) is added so that the object of determination becomes 2 to 4U / mL. After heating 3mL of the diluted solution at 37°C for 5 minutes, 0.05mL of the substrate solution is added. After that, the mixed solution is reacted at 37°C and the absorbance change at a wavelength of 240nm is measured. After reacting at 37°C, the absorbance change from 2 minutes to 7 minutes is measured to calculate the cholesterol oxidase activity. For example, if the absorbance change is more than 3U / L, it can be said that the object of determination has cholesterol oxidase activity, and more specifically, it can be said that it contains cholesterol oxidase.
[0133] In the determination of cholesterol esterase activity, substrate (0.04% cholesterol linoleate, 1% TritonX100, 0.6% sodium cholate solution), 300U / mL cholesterol oxidase solution, enzyme diluent (20mM phosphate buffer, 0.5mM EDTA·2Na, 2mM MgCl2, 0.2% bovine serum albumin (BSA), pH7.5), reaction solution (0.06% 4-aminoantipyrine, 0.4% phenol, 7.5KU / L peroxidase (POD)) were used. 1.75mL of the reaction solution was mixed with 1.0mL of the substrate solution, heated at 37°C for 5 minutes, and 0.1mL of the cholesterol oxidase solution was added. After heating at 37°C for 2 minutes, 0.1mL of the object to be measured diluted with the diluent was added, and the mixed solution was reacted at 37°C, and the absorbance change at a wavelength of 500nm was measured. The cholesterol esterase activity is calculated by measuring the absorbance change from 0 minutes to 3.5 minutes after the reaction at 37° C. For example, if the absorbance change is 8 U / L or more, it can be said that the measurement object has cholesterol esterase activity, and more specifically, it can be said that cholesterol esterase is contained.
[0134] The sphingomyelinase activity of the first reagent composition is measured, for example, by the following method. That is, a reaction solution (0.008% sphingomyelin, 0.05% TritonX100 solution, 10U / mL alkaline phosphatase, 10U / mL cholesterol oxidase, 2U / mL peroxidase, 0.02% 4-aminoantipyrine, 0.02% TODB mixed solution), a reaction stop solution (1% sodium dodecyl sulfate solution), and a diluent (10mM Tris buffer, 0.1% TritonX100, pH8.0) are used. 0.08mL of the reaction solution is mixed with 0.003mL of the object to be measured diluted with the diluent, and after heating at 37°C for 5 minutes, 0.16mL of the reaction stop solution is added. After the reaction is terminated, the absorbance changes at the main wavelength of 546nm and the sub-wavelength of 700nm are measured to calculate the sphingomyelinase activity. For example, when the amount of change in absorbance is 2 U / L or more, it can be said that the measurement object has sphingomyelinase activity, and more specifically, it can be said that it contains sphingomyelinase.
[0135] The peroxidase activity of the first reagent composition is measured, for example, by the following method. That is, reaction solution 1 (1.5mM HDAOS, 0.05% TritonX100, 50mM phosphate buffer, pH7.0), reaction solution 2 (5mM 4-aminoantipyrine, 0.05% TritonX100, 1% hydrogen peroxide, 50mM phosphate buffer, pH7.0), and diluent (50mM phosphate buffer, pH7.0) are used. 0.3mL of reaction solution 1 is mixed with 0.08mL of the object to be measured diluted with the diluent, and heated at 37°C for 5 minutes. Then, 0.1mL of reaction solution 2 is added, reacted at 37°C, and the absorbance change at the main wavelength of 600nm and the sub-wavelength of 700nm is measured. The absorbance change from 2 minutes to 5 minutes after the reaction at 37°C is measured to calculate the peroxidase activity. For example, when the amount of change in absorbance is 10 U / L or more, it can be said that the measurement object has peroxidase activity, and more specifically, it can be said that it contains peroxidase.
[0136] The catalase activity of the first reagent composition is measured, for example, by the following method. That is, in the determination of catalase activity, a substrate (0.06% hydrogen peroxide, 50mM phosphate buffer, pH 7.0) is used. After preheating 2.0mL of the substrate solution at 25°C, it is mixed with 0.1mL of the object to be measured, and the change in absorbance at 240nm is measured. For example, the change in absorbance from 0 minutes to 3 minutes after the reaction at 25°C is measured to calculate the catalase activity. For example, if the change in absorbance is 50U / L or more, it can be said that the object to be measured has catalase activity, and more specifically, it can be said that it contains catalase.
[0137] The first reagent composition may further have other enzyme activities, and specifically, may further have one or two or more enzyme activities selected from the group consisting of ascorbic acid oxidase activity and lipoprotein lipase (LPL) activity.
[0138] In addition, the first reagent composition may contain, for example, one or more enzymes having enzyme activity selected from the group consisting of an enzyme having ascorbate oxidase activity and an enzyme having lipoprotein lipase activity, more specifically, one or more enzymes selected from the group consisting of ascorbate oxidase and lipoprotein lipase.
[0139] From the viewpoint of avoiding the influence of ascorbic acid coexisting in the sample on the accuracy of the measurement, the first reagent composition preferably further has ascorbic acid oxidase activity, and more preferably has ascorbic acid oxidase activity.
[0140] From the same viewpoint, the first reagent composition preferably contains an enzyme having ascorbic acid oxidase activity, and more preferably contains ascorbic acid oxidase.
[0141] From the viewpoint of avoiding the influence of ascorbic acid coexisting in the sample on the accuracy of the measurement, the ascorbate oxidase activity of the first reagent composition is preferably 0.1 U / mL or more, more preferably 0.2 U / mL or more, and is preferably 15 U / mL or less, more preferably 10 U / mL or less.
[0142] The ascorbate oxidase activity of the first reagent composition is measured, for example, by the following method. That is, in the ascorbate oxidase activity assay, a substrate (a 10mM ascorbic acid solution-0.13mM EDTA is diluted 20 times with 90mM KH2PO4-5mMNaHPO4) is used. 1mL of the substrate is preheated at 30°C, and after 5 minutes, 0.1mL of the assay object diluted with a 90mM NaHPO4 solution containing 0.05% BSA is added and mixed to start the reaction. After 5 minutes, 3.0mL of a reaction stop solution (0.2N HCl) is added to terminate the reaction, and the absorbance at 245nm is measured to calculate the ascorbate oxidase activity. For example, if the activity amount is 10U / L or more, it can be said that the assay object has ascorbate oxidase activity, and more specifically, it can be said that it contains "ascorbate oxidase".
[0143] From the viewpoint of preferably regulating the action on various lipoproteins, the lipoprotein lipase activity of the first reagent composition is preferably 2 U / mL or more, more preferably 50 U / mL or more, and is preferably 300 U / mL or less, more preferably 200 U / mL or less.
[0144] The lipoprotein lipase activity of the first reagent composition is measured, for example, by the following method. That is, in the determination of lipoprotein lipase activity, an olive oil emulsion solution (5 mL of 5.0% TritonX100 is added to 5 g of olive oil and 2 mL of ethanol, ultrasonic treatment is performed for 20 minutes, and then 25 mL of 4% BSA and 15 mL of 0.1 M phosphate buffer pH 7.0 are added, and the solution is stirred at room temperature for 1 to 2 hours). A diluent (20 mM phosphate buffer, 2 mM MgCl2, 0.5 mM EDTA-2Na, pH 7.5) is added to the substrate solution preheated at 37°C for 5 minutes to make 0.9 to 1.6 U / mL, 0.2 mL of the diluted test sample is added, and after heating at 37°C for 15 minutes, 2.0 mL of a reaction stop solution (0.2 M trichloroacetic acid) is added. After that, filtration (Toyo filter paper No. 131 or Whatman No. 42) is performed to recover the filtrate. 3.0 mL of a colorimetric reagent (200 mL of 50 mM MES-NaOH buffer, 4 mL of 5% TritonX100, 40 μL of N,N-dimethyl-m-methylaniline, 4 mg of 4-aminoantipyrine, 24.2 mg of ATP·2Na·3H2O, 40.7 mg of MgCl2·6H2O, 200 U of glycerol kinase, 500 U of Lα glycerol phosphate oxidase, and 300 U of peroxidase) was added to 0.05 mL of the filtrate, and the mixed solution was reacted at 37°C for 15 minutes, and the absorbance at a wavelength of 545 nm was measured to calculate the lipoprotein lipase activity. For example, if the absorbance change is 3 U / L or more, it can be said that the measurement object has lipoprotein lipase activity, and more specifically, it can be said that lipoprotein lipase is contained.
[0145] The lipoprotein lipase is not limited as long as it is an enzyme capable of degrading lipoprotein, and for example, lipoprotein lipase derived from animals or microorganisms can be used.
[0146] In addition, in the present embodiment, the enzyme in the first reagent composition and the second reagent composition described later can also be identified by the following method. That is, first, using a hybrid mass spectrometer, the fragment peptide obtained by degrading the sample containing the target enzyme with trypsin is detected. The mass of the peptide obtained by the mass spectrometer and the spectrum (MS / MS data) of the fragment ions obtained by colliding with argon gas in the mass spectrometer are searched in the database (for example, Mascot search), so that the protein can be identified. When the sequence of the fragment peptide derived from the amino acid sequence in the reagent composition is consistent with the amino acid sequence registered in the database as a unique sequence, it can be considered that the target enzyme is contained.
[0147] In addition, the enzyme in the first reagent composition and the second reagent composition described later can also be identified by the following quantification, for example. That is, the target enzyme specificity among the fragment peptides obtained by degrading the target enzyme with trypsin and the peptide that obtains a strong signal in the mass spectrum is selected as the quantitative object peptide. For the quantitative object peptide, non-labeled peptides and stable isotope-labeled peptides as internal standards are made by chemical synthesis. The sample containing the target enzyme is completely digested by trypsin, and a known amount of stable isotope-labeled peptides is added, and the triple quadrupole mass spectrometer (LC-MS / MS) connected to HPLC is measured in MRM mode (multiple reaction monitoring mode). Similarly, the mixed solution of the non-labeled peptide of the quantitative object peptide and the known amount of the stable isotope-labeled peptide is measured, and the standard curve of the concentration ratio and the peak area ratio of the internal standard is made. By calculating the absolute amount of the quantitative object peptide in the sample, the target enzyme can be quantified.
[0148] (Other ingredients)
[0149] The first reagent composition may contain components other than the above-mentioned components. Examples of other components include buffers, salts, proteins that do not have an enzyme action, preservatives such as sodium azide, hydrogen donors, and coupling agents.
[0150] The type of buffer can be appropriately selected, for example. Specific examples of the buffer include MOPS (3-morpholinopropanesulfonic acid) buffer, phosphate buffer, Tris buffer, PIPES (piperazine-1,4-bis(2-ethanesulfonic acid)) buffer, and HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer.
[0151] From the viewpoint of maintaining the enzyme activity in the composition and improving the storage stability of the reagent, the concentration of the buffer solution is preferably 1 mM or more, more preferably 5 mM or more, further preferably 10 mM or more, and is preferably 300 mM or less, preferably 200 mM or less, further preferably 150 mM or less, and further more preferably 100 mM or less.
[0152] Specifically, the salt is added as a pH adjuster or an ionic strength adjuster. Specific examples of the salt include sodium salts such as sodium hydroxide and sodium sulfate; potassium salts such as potassium hydroxide; magnesium salts such as magnesium chloride and magnesium sulfate; and alkaline substances such as ammonium salts such as ammonium sulfate and ammonium chloride. In addition, by making the first reagent composition contain at least one of a monovalent cation and a divalent cation or a salt thereof, it becomes easier to distinguish between sdLDL and L LDL.
[0153] From the viewpoint of functioning more stably as a pH adjuster or an ionic strength adjuster, the salt concentration in the first reagent composition is preferably 2 mmol / L or more, more preferably 5 mmol / L or more, and is preferably 50 mmol / L or less, more preferably 30 mmol / L or less, relative to the entire composition of the first reagent composition.
[0154] From the viewpoint of maintaining the enzyme activity in the composition and improving the storage stability of the reagent, the pH of the first reagent composition is preferably 6.0 or higher, more preferably 6.5 or higher, and is preferably 8.0 or lower, more preferably 7.5 or lower.
[0155] Specific examples of proteins that do not have an enzyme action include albumins such as bovine serum albumin (BSA).
[0156] From the viewpoint of stabilizing the enzyme in the first reagent composition and stabilizing the first step (which exports cholesterol in lipoproteins other than sdLDL to the outside of the reaction system), the concentration of albumin such as BSA in the first reagent composition is preferably 1 g / L or more, more preferably 2 g / L or more, and is preferably 20 g / L or less, more preferably 10 g / L or less, relative to the entire composition of the first reagent composition.
[0157] The first reagent composition preferably contains at least one of a hydrogen donor and a coupling agent, and more preferably contains any one of a hydrogen donor and a coupling agent. In this case, any one of the hydrogen donor and the coupling agent is used to export cholesterol in lipoproteins other than sdLDL to the outside of the reaction system in the first step. More specifically, any one of the hydrogen donor and the coupling agent is used so that cholesterol esterase and cholesterol oxidase act on cholesterol in lipoproteins other than sdLDL, and the generated hydrogen peroxide is converted into colorless quinone in the presence of peroxidase.
[0158] Specific examples of the hydrogen donor include aniline derivatives such as N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline (TOOS), N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (MAOS), N-ethyl-N-(3-sulfopropyl)-3-methylaniline (TOPS), N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (HDAOS), N-(3-sulfopropyl)aniline (HALPS), N-(3-sulfopropyl)-3-methoxy-5-aniline (HMMPS), N-ethyl-N-(2-hydroxy-3-sulfopropyl)-4-fluoro-3,5-dimethoxyaniline (FDAOS), and N-ethyl-N-(3-methylphenyl)-N'-succinylethylenediamine (EMSE).
[0159] From the viewpoint of exporting cholesterol in lipoproteins other than sdLDL to the outside of the reaction system, the concentration of the hydrogen donor in the first reagent composition is preferably 1 mM or more, more preferably 1.5 mM or more, and is preferably 5 mM or less, more preferably 3 mM or less.
[0160] In addition, when a hydrogen donor is used in the second reagent composition described later, it is preferred that a coupling agent used in the coupling reaction is included in the first reagent composition. As the coupling agent, for example, 4-aminoantipyrine (4AA), aminoantipyrine derivatives, vanillin diamine sulfonic acid, methylbenzothiazolinone hydrazone, sulfonated methylbenzothiazolinone hydrazone, etc. can be used, but it is not limited to these.
[0161] From the viewpoint of stably acting on sdLDL, the concentration of the coupling agent in the first reagent composition is preferably 0.2 mM or more, more preferably 0.3 mM or more, and is preferably 5.0 mM or less, more preferably 3.3 mM or less, relative to the total composition of the reaction solution after adding the first reagent composition.
[0162] (Reagent test kit)
[0163] In the present embodiment, the kit is used for quantifying sdLDL-C in a sample, and includes the above-mentioned first reagent composition and a second reagent composition for quantifying sdLDL-C.
[0164] In addition, the kit is specifically used for a quantitative method of sdLDL-C including two or more steps. In this case, the first and second reagent compositions are used in different steps, respectively, and the first and second reagent compositions are preferably used in this order.
[0165] Hereinafter, the configuration of the second reagent composition will be described in more detail.
[0166] (Second reagent composition)
[0167] The second reagent composition is specifically a reagent composition for quantifying sdLDL-C. The components of the second reagent composition differ depending on the constitution of the first reagent composition, but any known substances may be used as long as the composition is such that sdLDL-C can be quantified.
[0168] Specific examples of the components contained in the second reagent composition include enzymes, buffers, salts, surfactants, proteins that do not have an enzyme action, preservatives, and any of hydrogen donors and coupling agents.
[0169] In a preferred configuration of the kit, the first reagent composition contains one of the hydrogen donor and the coupling agent but not the other, and the second reagent composition contains not one of the hydrogen donor and the coupling agent but contains the other.
[0170] As an enzyme, for example, peroxidase can be cited. In addition, the second reagent composition, for example, has peroxidase activity. From the viewpoint of accurately measuring sdLDL-C in the second step, the peroxidase activity of the second reagent composition is preferably 500U / L or more, more preferably 1000U / L or more, and preferably 10000U / L or less. Among them, when the first reagent composition contains peroxidase activity, the peroxidase activity will also be brought into the second step, so the concentration in the second reagent can also be reduced or not included.
[0171] The types of the buffer and the salt can be appropriately selected, for example, depending on the type of the enzyme contained in the second reagent composition. Specific examples of the buffer include those described above for the first reagent composition.
[0172] From the viewpoint of maintaining the enzyme activity in the composition and improving the storage stability of the reagent, the pH of the second reagent composition is preferably 6.0 or higher, more preferably 6.5 or higher, and is preferably 8.0 or lower, more preferably 7.5 or lower.
[0173] Examples of the surfactant include surfactants that act on sdLDL. In addition, from the viewpoint of stably quantifying sdLDL-C, the second reagent composition preferably contains a surfactant that acts on sdLDL.
[0174] The surfactant acting on sdLDL may be a surfactant that selectively acts on sdLDL, such as a surfactant that acts only on sdLDL, or may be a surfactant that acts on lipoproteins other than sdLDL or a surfactant that acts on all lipoproteins.
[0175] As the surfactant in the second reagent composition, for example, polyoxyethylene derivatives can be mentioned, and in addition, surfactants used in commercially available total cholesterol measurement reagents can be used. As the surfactant, for example, polyoxyethylene alkylphenyl ethers such as polyoxyethylene octylphenyl ether (for example, Emulgen 909 (manufactured by Kao Corporation), Triton X-100), polyoxyethylene alkyl ethers (for example, Emulgen 707, Emulgen 709 (manufactured by Kao Corporation)) can be mentioned.
[0176] From the viewpoint of stably acting on sdLDL, the concentration of the surfactant in the second reagent composition is preferably 0.05% (w / v) or more, more preferably 0.1% (w / v) or more, and even more preferably 0.5% (w / v) or more, relative to the mixed solution after adding the second reagent composition.
[0177] From the same viewpoint, the concentration of the surfactant in the second reagent composition is preferably 8.0% (w / v) or less, and more preferably 5.0% (w / v) or less.
[0178] When the second reagent composition contains a coupling agent, the coupling agent is preferably one or two or more compounds selected from the group consisting of 4-aminoantipyrine (4-AA), aminoantipyrine derivatives, vanillin diamine sulfonic acid, methylbenzothiazolinone hydrazone, and sulfonated methylbenzothiazolinone hydrazone.
[0179] From the viewpoint of stably acting on sdLDL, the concentration of the coupling agent in the second reagent composition is preferably 0.5 mM or more, more preferably 1.0 mM or more, and is preferably 15 mM or less, more preferably 10 mM or less, relative to the total composition of the reaction solution after adding the second reagent composition.
[0180] On the other hand, when the first reagent composition contains a coupling agent, the hydrogen donor is preferably contained in the second reagent composition. As specific examples of the hydrogen donor, the hydrogen donor described above for the first reagent composition can be cited. From the viewpoint of stably acting on sdLDL, the concentration of the hydrogen donor in the reagent in this case is preferably 3 mM or more, more preferably 4.5 mM or more, and preferably 15 mM or less, more preferably 12 mM or less, relative to the entire composition of the reaction solution after adding the second reagent composition.
[0181] Specific examples of the protein and preservative that do not have an enzyme action include the specific examples described above for the first reagent composition.
[0182] (method)
[0183] The method of the present embodiment is a method for quantifying sdLDL-C in a sample using the first and second reagent compositions described above. The quantification method of the present embodiment includes the following first and second steps.
[0184] (First step) A step of allowing the first reagent composition to act on a sample
[0185] (Second step) After the first step, a step of allowing the second reagent composition to act to quantify the cholesterol in the remaining lipoprotein
[0186] The first and second reagent compositions are as described above. In the method, by using the first reagent composition of the present embodiment, it is possible to perform a measurement with excellent accuracy and specificity after the sample is diluted, and thus, for example, it is also possible to stably quantify sdLDL-C as a reagent having good dilution linearity and high correlation with a reference method.
[0187] The quantitative method of sdLDL-C may be performed, for example, by adding the first reagent composition to a sample (test specimen) to allow the reaction to proceed, then adding the second reagent composition to allow the reaction to proceed, and measuring the absorbance.
[0188] The test sample is, for example, a blood-derived sample such as serum or plasma, and is preferably serum.
[0189] The first and second steps are usually performed in an automatic analyzer.
[0190] The amount of the sample and the amount of each reagent composition can be appropriately determined, for example, in consideration of the concentration of the reagent in each reagent composition, within a range that can be applied to an automatic analyzer. For example, 1 to 10 μL of the test sample, 50 to 300 μL of the first reagent, and 25 to 200 μL of the second reagent can be used.
[0191] Hereinafter, each step will be described in more detail.
[0192] (1st step)
[0193] In the first step, the first reagent composition is allowed to act on the sample, thereby removing lipoproteins other than sdLDL and releasing cholesterol in lipoproteins other than sdLDL to be removed from the reaction system.
[0194] More specifically, in the first step, it is preferred that a surfactant acting on lipoproteins other than sdLDL is allowed to act on the sample in the presence of sphingomyelinase and cholesterol esterase. Then, cholesterol generated by dissociation from lipoproteins is reacted with an enzyme such as cholesterol oxidase (which reacts with cholesterol) and exported to the outside of the reaction system. In the first step, for example, the following techniques can be used: cholesterol in lipoproteins other than sdLDL is removed and exported to the outside of the reaction system, cholesterol in lipoproteins other than sdLDL is agglomerated, or it is inhibited so that it does not react in subsequent steps, and other known techniques.
[0195] When the first reagent composition has an electron donor, in the first step, the step of removing cholesterol produced from lipoproteins other than sdLDL and exporting it outside the reaction system may include, for example, the following step: forming a colorless quinone in the presence of hydrogen peroxide and an electron donor produced by sphingomyelinase, cholesterol esterase activity and cholesterol oxidase activity in the first reagent composition.
[0196] In the first step, at least one of monovalent cations and divalent cations or salts thereof may be further added to the reaction solution as an ionic strength adjuster. The addition of the ionic strength adjuster facilitates differentiation between sdLDL and LLDL.
[0197] (Second step)
[0198] In the second step, the sdLDL-C remaining after the first step is quantified. In the second step, a conventional method for quantifying LDL can be used. For example, there are methods for quantifying the content of LDL-specific aggregates formed by adding an LDL aggregating agent by turbidimetry, methods using antigen-antibody reactions using LDL-specific antibodies, and methods for quantifying degradation products using enzymes. The quantification method can be selected, for example, based on the components and composition contained in the second reagent composition.
[0199] When the second reagent composition contains an enzyme, a method of quantifying the degradation product using the enzyme can be adopted. Specifically, a second reagent composition containing one or more cholesterol measuring enzymes selected from the group consisting of cholesterol esterase, cholesterol oxidase, cholesterol dehydrogenase and peroxidase is added to the reaction solution after the first step to release and degrade sdLDL-C, and the reaction product is quantified.
[0200] In the present embodiment, the reaction temperature in each step is preferably 2°C to 45°C, more preferably 25°C to 40°C.
[0201] The reaction time for each step is preferably 1 to 10 minutes, more preferably 3 to 7 minutes.
[0202] Examples of automatic analyzers used for quantification of sdLDL-C include TBA-120FR, TBA-200FR (all manufactured by Toshiba Corporation), JCA-BM1250, JCA-BM1650, JCA-BM2250 (all manufactured by NEC Corporation), HITACHI7180, HITACHI7170 (all manufactured by Hitachi, Ltd.), AU2700, AU5800, AU680 (all manufactured by OLYMPUS Corporation), cobas c501, cobas c701 (all manufactured by Roche Corporation), etc.
[0203] The quantification of sdLDL-C is performed, for example, by measuring absorbance in a wavelength range of 580 to 720 nm, preferably in a wavelength range of 600 to 700 nm.
[0204] As mentioned above, although embodiment of this invention was described, these are an example of this invention, and various structures other than the above-mentioned can also be adopted.
[0205] Example
[0206] (Examples 1 to 7, Comparative Examples 1 and 2)
[0207] The first reagent composition of each example with a changed contact angle was prepared and combined with the second reagent composition to perform quantification of sdLDL-C, and the accuracy and specificity (correlation with the standard method) of the measured sample after dilution were evaluated.
[0208] (Preparation of Reagent Composition)
[0209] The first reagent composition and the second reagent composition of each example were prepared by mixing the following components at the following concentrations.
[0210] Regarding the first reagent composition, the type and concentration of the nonionic surfactant were changed to prepare compositions of various examples.
[0211] The formulations of the first reagent composition and the second reagent composition used in the measurement are shown below.
[0212] (First reagent composition)
[0213]
[0214] Nonionic surfactant*1
[0215] *1 Nonionic surfactant: A polyoxyethylene benzyl phenyl ether derivative and a polyoxyethylene styrenated phenyl ether derivative were used, and the amounts thereof added were varied to adjust to the first reagent compositions a to i.
[0216] (Second reagent composition)
[0217]
[0218] (Measurement of sdLDL-C)
[0219] The sdLDL-C was measured using the first reagent composition and the second reagent composition of each example. Specifically, the first reagent composition and the second reagent composition with different contact angles were prepared in each example. 150 μL of the first reagent composition was added to 3 μL of the serum sample, reacted at 37°C for 5 minutes, and then 50 μL of the second reagent composition was added and reacted for 5 minutes. The absorbance at the main wavelength of 600 nm and the sub-wavelength of 700 nm was measured, and the sdLDL-C concentration was calculated from the standard curve.
[0220] (Contact Angle Measurement Method)
[0221] As the PET substrate, a visually transparent PET (amorphous polyester) resin plate (manufactured by CITAKIRON Corporation, PET plate (PETEC) model 6010, thickness 2 mm) was used. The surface of an unused PET substrate was wiped with a 70% ethanol aqueous solution and then measured within 5 minutes.
[0222] The contact angle was measured using a contact angle meter (DMo-501 manufactured by Kyowa Interface Science Co., Ltd.) by the drop method and the θ / 2 method at a temperature of 15 to 25°C, a syringe of Teflon-coated 18G, a dropping method, and a dropping amount of 2 μL, 1 second after dropping.
[0223] The measurement was performed 5 times for each example, and the average value of the 5 times was calculated. The measurement results are shown in Table 1.
[0224] (Method for measuring viscosity)
[0225] For the embodiments and comparative examples, an EMS viscometer (EMS-1000 manufactured by Kyoto Electronics Industry Co., Ltd.) was used to measure the viscosity of the first reagent composition of each example using an electromagnetic rotation method, with the motor speed being 1000 rpm, the holding time being 600 seconds, the measuring temperature being 5° C. and 37° C., the sequential cycle being 1 time, and the sample being 500 μL. For each example, 5 measurements were performed at each temperature, and the average value of the 5 measurements was calculated. The measurement results are shown in Table 1.
[0226] (Accuracy test after sample dilution)
[0227] Human serum with known sdLDL-C concentrations was diluted 2-fold with physiological saline, and the sdLDL-C concentrations in each case before and after the dilution were measured. The measured value of the diluted sample was multiplied by the dilution factor 2 and compared with the measured value before the dilution to calculate a univariate regression equation.
[0228] The summary of the measurement results is shown in Table 1. In addition, the detailed data of each case are shown in Figure 1 (a)~ Figure 1 (i). Figure 1 (a)~ Figure 1 In (i), the horizontal axis represents the measured value of the test sample before dilution, and the vertical axis represents the measured value of the test sample after dilution obtained by multiplying the dilution factor by 2. The evaluation criteria are shown below.
[0229] A: The slope of the univariate regression equation is within 1.00±0.06 (0.94~1.06), and the correlation coefficient r (the same below) of the univariate regression equation satisfies r>0.9 (r 2 >0.81)
[0230] B: The slope of the univariate regression equation is greater than 1.00±0.06 and within 1.00±0.10, and r>0.9 (r 2 >0.81)
[0231] C: The slope of the univariate regression equation is greater than 1.00±0.10, or r≤0.9 (r 2 ≤0.81)
[0232] According to Table 1 and Figure 1 (a)~ Figure 1 (i) in each embodiment, good accuracy after sample dilution was obtained.
[0233] (Correlation test with the benchmark method)
[0234] As a comparative method, the value of sdLDL-C (specific gravity 1.044 to 1.063) measured by ultracentrifugation in each human sample was calculated and compared with the sdLDL-C value of each case.
[0235] The summary of the measurement results is shown in Table 1. In addition, the detailed correlation data of each case is shown in Figure 2 (a)~ Figure 2 (i). Figure 2 (a)~ Figure 2 The horizontal axis of (i) represents the sdLDL-C value calculated by the ultracentrifugation method as the standard method, and the vertical axis represents the sdLDL-C value in each example. The evaluation criteria are shown below. The evaluations of A and B below were considered to be acceptable.
[0236] A: The slope is within 1.00±0.11 (0.89~1.11), and the correlation coefficient r of the univariate regression equation (the same below)>0.905 (r 2 >0.819)
[0237] B: The slope is greater than 1.00±0.11 and within 1.00±0.20, and r>0.900 (r 2 >0.810)
[0238] C: Slope greater than 1.000 ± 0.200, or 0.900 ≤ r(r 2 ≤0.81)
[0239] According to Table 1 and Figure 2 (a)~ Figure 2 (i) , a good correlation with the ultracentrifugation method was obtained in each example.
[0240] in addition, Figure 3 This is a graph showing the correlation coefficient when the reagent compositions are arranged in descending order of contact angle. As a result, the correlation coefficient becomes higher at the contact angles of reagent compositions b to h.
[0241] (Dilution Linearity Test)
[0242] A dilution linearity test was performed for Comparative Example 1 and Examples 2, 4, and 6 in the examples described in Table 1. Specifically, a high-concentration sdLDL-C sample with a known concentration was diluted with physiological saline in 10 stages, and the sdLDL-C concentration of each example in each dilution series was measured. The analysis was performed in accordance with the CLSI Guideline EP06-A, and a nonlinear difference plot was calculated to evaluate the dilution linearity.
[0243] The summary of the measurement results is shown in Table 1, and the detailed data are shown in Figure 4 (a)~ Figure 4 (d). Figure 4 (a)~ Figure 4 In the left figure of (d), the horizontal axis (dilute Lv.) represents the dilution series of the high-concentration sample, and the vertical axis (measured value [mg / dL]) represents the sdLDL-C value. Figure 4 (a)~ Figure 4 In the right figure of (d), the horizontal axis (dilution level (dilute Lv.)) represents the dilution series of the high concentration sample, and the vertical axis (non-linearity [mg / dL]) represents the non-linearity of the sdLDL-C value. The evaluation criteria are as follows in accordance with the CLSI Guideline EP06-A. The following evaluations of A and B are considered qualified.
[0244] A: Nonlinear value ( Figure 4 The circular plot points in the right figure) are within the allowable range at all points ( Figure 4 The inside of the two solid lines in the right figure: Linear fit within ±3 mg / dL for sdLDL-C < 30 mg / dL, linear fit within ±10% for sdLDL-C ≥ 30 mg / dL)
[0245] C: Nonlinear value ( Figure 4 The circular plot points in the right figure) are out of the allowable range at least one point ( Figure 4 The inside of the two solid lines in the right figure: Linear fit for sdLDL-C < 30 mg / dL ± 3 mg / dL, linear fit for sdLDL-C ≥ 30 mg / dL ± 10%)
[0246] According to Table 1 and Figure 4 (a)~ Figure 4 (d), good dilution linearity was obtained in each embodiment.
[0247] according to Figure 1 (a)~ Figure 1 (i) Figure 2 (a)~ Figure 2 (i) Figure 3 , Figure 4 (a)~ Figure 4 (d) and Table 1, in each example, it is possible to achieve sdLDL-C measurement with excellent dilution linearity, accuracy after sample dilution, and correlation with the standard method.
[0248] [Table 1]
[0249] Table 1
[0250]
[0251] (Examples 8 to 10)
[0252] (Preparation of Reagent Composition)
[0253] The following components were blended at the following concentrations, and the type of surfactant was changed to prepare the first reagent composition of each example. The blending composition of the first reagent composition is shown below.
[0254] (First reagent composition)
[0255]
[0256]
[0257] Surfactant*2
[0258] *2Surfactant
[0259] Example 8: POE monostyrenated phenyl ether, the degree of polymerization of POE is 11 to 33
[0260] Example 9: POE monostyrenated phenyl ether, the degree of polymerization of POE is 13 to 37
[0261] Example 10: Polyoxyethylene benzyl phenyl ether derivatives
[0262] (Evaluation of Lipoprotein Selectivity)
[0263] In order to evaluate the lipoprotein selectivity in the reaction using the first reagent composition, the reactivity of sdLDL and 1bLDL with the reagent composition was measured.
[0264] Specifically, sdLDL and 1bLDL separated from human serum by ultracentrifugation were used as test samples. A first reagent composition was prepared to confirm the reactivity of the surfactant to the test sample. During the evaluation, in order to generate a color reaction using only the first reagent composition and to simply evaluate by absorbance measurement, a composition obtained by combining 1.5 mM TOOS and 1250 U / L peroxidase instead of 1200 KU / L catalase in the above composition was used as the first reagent composition for evaluation of each example.
[0265] 3 μL of the test sample was mixed with 150 μL of the first reagent composition of each example, and the difference in absorbance at 600 nm (main wavelength) and 700 nm (sub-wavelength) after 5 minutes at 37°C (described as "absorbance wavelength 600 nm / 700 nm" in Table 2) [mAbs] was measured to determine the ratio of the absorbance of lbLDL to the absorbance of sdLDL. The measurement results are shown in Table 2.
[0266] [Table 2]
[0267] Table 2
[0268] Example 8 Example 9 Example 10 Contact Angle 63.8 65.5 66.1 POE monostyrenated phenyl ether (%) 0.17 0.17 0 Ib LDL absorbance (wavelength 600 / 700nm) 2563 3391 2911 sd LDL absorbance (wavelength 600 / 700nm) 1761 1768 2493 Ib LDL / sd LDL absorbance ratio 146 1.92 1.17
[0269] According to Table 2, by using the first reagent composition of each example, sdLDL in the sample can be more accurately quantified. In addition, according to Table 2, in each example, the absorbance ratio of LDL of the first reagent composition containing POE monostyrenated phenyl ether shows that the selectivity for lbLDL in the first step is more excellent.
[0270] (Comparative Example 3)
[0271] (Preparation of Reagent Composition)
[0272] In Examples 1 to 7, Comparative Examples 1 and 2, a first reagent composition using polyoxyethylene styrenated phenyl ether sulfate as an anionic surfactant was prepared according to the aforementioned method, the contact angle and viscosity were measured according to the methods in the above examples, and the accuracy after the dilution of the test sample was evaluated. In the measurement of the accuracy after the dilution of the test sample, instead of the first reagent composition of Comparative Example 3, a first reagent composition with the same formulation as that of the aforementioned Example 4 was prepared as a control, and the measurement was performed. The measurement results are shown in Table 3. Table 3 also shows the measurement results of the contact angle and viscosity of the aforementioned Example 4 (Table 1). In addition, the detailed data are shown in Figure 5 (a) and Figure 5 (b). Figure 5 (a) and Figure 5 (b) shows the measurement results of the first reagent composition having the same formulation as that of Example 4 and Comparative Example 3, respectively.
[0273] [Table 3]
[0274] Table 3
[0275]
[0276] according to Figure 5 (b) In Comparative Example 3 using an anionic surfactant, sdLDL could not be accurately quantified after diluting the test sample in the sample. On the contrary, in Example 4 using a nonionic surfactant ( Figure 5 In (a)), even after the sample is diluted, accurate quantification can be performed. Figure 5 (a) and Figure 1 (e) It was confirmed that, for the composition with the same formulation, the selectivity after dilution of the test sample can be evaluated with excellent reproducibility.
[0277] This application claims the benefit of priority based on Japanese patent application No. 2022-064966, filed on April 11, 2022, the disclosure of which is incorporated herein in its entirety.
Claims
1. A reagent composition for use as a first reagent composition in a method for quantifying small, dense LDL cholesterol (sdLDL-C) in a sample, the method comprising: a step of allowing the first reagent composition to act on the sample; and After the step of allowing the first reagent composition to act on the sample, a step of allowing a second reagent composition for quantifying sdLDL-C to act on the sample to quantify cholesterol in the remaining lipoprotein, The reagent composition comprises a nonionic surfactant, The reagent composition has cholesterol esterase activity, cholesterol oxidase activity and sphingomyelinase activity, The contact angle between the reagent composition and the polyethylene terephthalate (PET) substrate measured by the following method 1 is 63.0° or more and 67.0° or less, (Method 1) (1) PET substrate: PET (amorphous polyester) resin sheet, transparent, thickness 2 mm; (2) Pretreatment: Wipe the surface of an unused PET substrate with a 70% ethanol aqueous solution and perform the measurement within 5 minutes after wiping; (3) Measurement method and conditions: drop method, θ / 2 method, temperature: 15-25°C, syringe: Teflon-coated 18G, drop method, drop volume: 2 μL, measurement was performed 1 second after drop; (4) Calculation of contact angle: Measure 5 times and calculate the average value of the 5 times.
2. The reagent composition according to claim 1, wherein The viscosity of the reagent composition at 5°C measured by the following method 2-1 is 2.5 mPa·s or less, (Method 2-1) (1) Apparatus: EMS viscometer (Electro Magnetically Spinning Visco meter); (2) Measurement method and conditions: Measurement method: electromagnetic rotation method, motor speed: 1000 rpm, holding time: 600 seconds, measurement temperature: 5°C, sequential cycle: 1 time, sample: 500 μL; (3) Calculation of viscosity: The measurement was performed 5 times, and the average value of the 5 times was calculated.
3. The reagent composition according to claim 1 or 2, wherein The viscosity of the reagent composition at 37°C measured by the following method 2-2 is 1.05 mPa·s or less. (Method 2-2) (1) Apparatus: EMS viscometer (Electro Magnetically Spinning Visco meter); (2) Measurement method and conditions: Measurement method: electromagnetic rotation method, motor speed: 1000 rpm, holding time: 600 seconds, measurement temperature: 37°C, sequential cycle: 1 time, sample: 500 μL; (3) Calculation of viscosity: The measurement was performed 5 times, and the average value of the 5 times was calculated.
4. The reagent composition according to claim 1 or 2, wherein The nonionic surfactant comprises polyoxyethylene monostyrenated phenyl ether.
5. The reagent composition according to claim 4, wherein The polymerization degree n of the polyoxyethylene in the polyoxyethylene monostyrenated phenyl ether is 5 or more and 80 or less.
6. The reagent composition according to claim 4, wherein The content of the polyoxyethylene monostyrenated phenyl ether in the reagent composition is 0.05% (w / v) or more and 0.6% (w / v) or less relative to the entire reagent composition.
7. The reagent composition according to claim 1 or 2, wherein The reagent composition comprises any one of a hydrogen donor and a coupling agent.
8. The reagent composition according to claim 1 or 2, wherein The reagent composition also has ascorbic acid oxidase activity.
9. The reagent composition according to claim 1 or 2, wherein The reagent composition further has at least one activity selected from the group consisting of peroxidase activity and catalase activity.
10. A kit for quantifying the sdLDL-C in the sample, the kit comprising: A first reagent composition formed from the reagent composition according to claim 1 or 2; and A second reagent composition for quantifying the sdLDL-C.
11. The kit according to claim 10, wherein The second reagent composition has peroxidase activity.
Citation Information
Patent Citations
Method and reagent for measuring lipoprotein cholesterol
JP2000325097A
